Q&A: The new CEO of biotech’s top trade group on China, vaccines, and Trump

Taking stock of the drug industry, from the lab to the medicine chest

July 18, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy BIO STAT+ | Q&A: The new CEO of biotech's top trade group on China, vaccines, and Trump Crowley discussed his relationship with Trump, his pitch to keep members in the group, and his views on controversial legislation. By Rachel Cohrs Zhang and John Wilkerson Vaccination slashes risk of long Covid, says large study tracing cases through Delta and Omicron variants As the coronavirus evolves, the gap between vaccinated and unvaccinated is increasing, and long Covid symptoms are changing. By Elizabeth Cooney Bone marrow donors needn't be perfect match, study says, paving way for more equitable access Using a particular drug greatly reduced complications, opening a way to boost donor matches, particularly for minority cancer patients. By Angus Chen Adobe Opinion: IRBs fail to assess trials' scientific merit, putting participants at risk Institutional review boards (IRBs) need to assess trials' scientific merit to protect volunteers from low-quality research. By Spencer Phillips Hey and Michael S. Wilkes

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser